Between 1985 and 1996, 18 patients with diffuse centrocytic lymphoma (DCL), including nine patients with an established histological and phenotypic diagnosis of mantle cell lymphoma (MCL), received 19 courses of high-dose chemotherapy (HDCT) followed by hematopoietic stem cell transplantation. Five patients received HDCT as consolidation treatment after first-line standard chemotherapy, and 14 after a relapse or progression, including one patient in early relapse after the first transplant. Six patients (33%) were in complete response (CR) prior to HDCT and 12 (67%) were in partial response: 10 (83%) of these 12 patients achieved CR at day 60 following HDCT. With a median followup of 30 months after HDCT, the 2-year overall and progression-free survivals of the whole series are 91 and 75%, respectively. The 2-year progression-free survivals are 74 and 75%, respectively, in the MCL and DCL subgroups.
Mantle cell lymphoma (MCL) is a lymphoid neoplasm arising from cells of the follicular mantle zone, which constitutes a new entity within the new revised European-American classification (REAL) of lymphomas. 1, 2 Most MCL were previously categorized in the diffuse centrocytic NHL (DCL) subgroup of the Kiel classification and within the diffuse small cleaved cell NHL (DSCL) subgroup of the working formulation. 1, [3] [4] [5] The diagnosis of MCL on the sole basis of histology is often difficult and phenotypic criteria (CD20 + , CD5 + , CD10 − , CD23
−/+
) are now required. 1, 4, 5 The molecular hallmark of MCL is the t(11;14)(q13;q32) translocation involving the PRAD1/CCND1 gene within the bcl-1 locus (reviewed in Ref. 5) . In all reported series, patients with MCL and DCL have a poor complete response rate to conventional chemotherapy, and a median disease-free and overall survival in the range of 18 and 40 months, respectively. [6] [7] [8] [9] [10] [11] High-dose chemotherapy with hematopoietic stem cell transplantation (HDCT) has been reported to improve the overall survival of patients with aggressive NHL in relapse 12 or with aggressive NHL with an international prognostic index (IPI) above 2 13 treated with first-line chemotherapy.
14 This therapeutic approach could therefore be useful in patients with DCL or MCL. We report herein a retrospective study of all 18 patients with MCL or DCL treated with HDCT as consolidation after first or second line conventional chemotherapy in the Centre Léon Bérard between 1986 and 1996.
Patients and methods
Among the 189 patients treated with HDCT for NHL in the Centre Léon Bérard between 1985 and 1996, 18 (9%) patients (15 males and three females) had a histological diagnosis of DCL (n = 9) or MCL (n = 9) after histological review according to previously defined criteria.
1,11 All patients with DCL or MCL treated with HDCT at the Centre Léon Bérard were included in the present study. Histological and immunohistochemical diagnosis was performed on lymph nodes, bone marrow and/or tissue biopsies. All patients had positive expression of CD20. In nine patients, the diagnosis of MCL could be demonstrated after a review including histological and phenotypic criteria (CD5 + , CD10 − ) in nine patients. The karyotype of the tumor is available in four of the nine MCL patients, all four showing the typical t(11,14)(q13,q32). In the nine remaining patients, the analysis of CD5 and CD10 could not be performed retrospectively and a histological diagnosis of diffuse centrocytic lymphoma was established. Lymphocytic and MALT lymphomas were excluded from this study.
Hematopoietic stem cells were collected from the bone marrow (n = 7) or from the peripheral blood after stimulation by G-CSF (5-10 g/kg/day) (n = 12 + cells/kg, respectively. The high-dose regimens used (n = 19) were cyclophosphamide (60 mg/kg, 2 days) with total body irradiation (TBI) in 11 patients (TBI, 12 Gy in six fractions for seven patients aged under 61 years, 10 Gy in five fractions for four patients aged above 60 years). The BEAM and BEAC regimens (BCNU, etoposide, ara-C, with melphalan or cyclophosphamide) were both used in three patients. 12 One patient received the ECA regimen (VP16, 800 mg/m 2 ; carboplatin, 1600 mg/m 2 , ara-C, 12 g/m 2 ). A patient relapsing 4 months after the first HDCT with BEAM received a second HDCT with cyclophosphamide-TBI 12 Gy as second consolidation after conventional salvage therapy.
The overall survival was calculated from the date of transplant until death or last date known to be alive. Progression-free survival was calculated from the date of transplantation until progression or last date known to be alive for patients free from progression after HDCT. Survival curves were plotted using the method of Kaplan-Meier. Survival curves were compared using the logrank test.
Results

Patient characteristics
The characteristics of the patients are presented in Table 1 . Median age at transplantation was 50 years (24-64). At initial diagnosis, 17 (94%) had a clinical stage III or IV, and the median IPI was 2 (range 1-5). Five (28%) patients were aged above 60 years. Among the nine MCL, seven tumors exhibited a diffuse pattern of growth and two both a nodular and diffuse pattern of growth.
Five MCL patients received HDCT as consolidation when achieving partial response (PR) or complete response (CR) after first-line treatment. Three patients (two with MCL) were primary refractory to first-line chemotherapy with cyclophosphamide-doxorubicin (n = 2) or DHAP (n = 1) and received HDCT while in remission after a conventional second-line chemotherapy. The remaining 10 patients (two MCL, eight DCL) were transplanted in first relapse after reinduction by conventional chemotherapy. Among the 13 patients with either primary refractory disease or relapse, 12 (92%) had stage III or IV disease; the median IPI at relapse was 3 (range 1-4).
Response to HDCT and survival
After HDCT, the median duration of neutropenia Ͻ500/l and thrombocytopenia Ͻ50 × 10 3 /l were 13 days (range 8-30) and 13 days (range 11-45), respectively. No toxic death was observed. Twelve (67%) patients received HDCT while in PR and six (33%) while in CR after conventional chemotherapy. At day 60 post-HDCT, 16 of the 18 (88%) patients were in CR, and therefore 10 (83%) of the 12 patients in PR before HDCT achieved a CR after HDCT. Two (12%) patients remained in PR at day 60 post-HDCT: a patient with MCL (No. 06) achieved a CR with surgery and is alive NED (at 11+ months); a patient (No. 14) with DCL is alive NED at 8 years without further treatment.
The median follow-up since transplantation and initial diagnosis is 32 months (range 10-139) and 54 (18-165) months, respectively; two patients have less than 1 year follow-up after HDCT (10 months each). The 2-year overall and progression-free survivals are 91 and 75% respectively (Figure 1a) . Six patients relapsed at 3, 3, 4, 15, 29 and 81 months after HDCT, and four died from the disease. The patient (No. 10) who relapsed 4 months after HDCT with BEAM is in CR 30 months after a second HDCT with cyclophosphamide-TBI. Progression-free survival at 24 months from the date of HDCT is not significantly different in patients with MCL and DCL (74 vs 75% P = 0.93, Figure 1b ). Patients treated with HDCT in first-and secondline therapy, have a similar progression-free (53 vs 82% at 2 years, P = 0.52) and overall survival (66 vs 89% at 2 years, P = 0.55). Patients treated with TBI or non-TBIcontaining regimens had a similar progression-free survival (77 vs 71% at 2 years, P = 0.57). Age, performance status, clinical stage, bone marrow involvement, serum LDH, or the international prognostic index prior to HDCT were not found correlated to progression-free or overall survival in this series (P Ͼ 0.3). The two patients with a MCL exhibiting both a nodular and a diffuse pattern of growth had a poor outcome after HDCT (relapse 3 and 15 months after HDCT) as compared to the seven remaining MCL patients (no progression after HDCT); however, the number of patients are too small to draw any definitive conclusion regarding this point. Patients who received a bone marrow graft (n = 7) and a PBSC graft (n = 11) had a similar progression-free and overall survival.
Discussion
The outcome of patients with MCL or DCL is consistently poor in the literature: (1) a complete response rate is achieved in only 9% to 51% of patients; (2) the median relapsefree survival ranges from 10 to 18 months; and (3) the median overall survival ranges from 36 to 52 months. [6] [7] [8] [9] [10] [11] These patients are therefore candidates for innovative therapies. The published experience of HDCT in MCL and DCL is limited. [15] [16] [17] [18] Stewart et al 15 reported nine patients with MCL in relapse treated with HDCT who achieved a 2-year overall and progression-free survival of 34%. Haas et al 16 reported a series of 13 patients with MCL treated with HDCT as consolidation in first-line or in relapse. With a median follow-up of 18 months post-HDCT, these authors report a 73% progression-free survival at 18 months and a 92% overall survival at 18 months. 16 The results of these two series compare favorably with those achieved with conventional chemotherapy in MCL or DCL.
The results presented in this retrospective series with a median follow-up of 32 months are consistent with these observations. They further indicate that HDCT is capable of inducing a high rate of complete remission in patients in PR prior to HDCT, in agreement with a recent presentation. 18 Although this population is selected, since most patients responded to conventional chemotherapy, a majority were in relapse or even primary refractory to firstline chemotherapy, and therefore were expected to have a very poor prognosis with conventional chemotherapy. 8 In this series, relapse-free and overall survival after HDCT were both above 70% at 2 years, in patients with MCL as well as in patients with DCL in whom a full phenotype was not available. This indicates that HDCT is a promising treatment option in patients with MCL and DCL, even in patients with primary refractory disease, when a response to conventional salvage therapy is achieved. None of the established prognostic criteria for NHL significantly influenced the survival of patients, possibly because of the small number of patients in this series. The two patients with a MCL exhibiting a nodular and diffuse pattern of growth were found to have a worse outcome after HDCT than patients with a diffuse subtype. However, larger series are required to confirm this point.
At the present time, the optimal HDCT regimen for MCL or DCL is not known, and in this series the outcome of patients treated with TBI-containing regimens was not significantly different from that of other patients. Interestingly, however, a patient with DCL who relapsed in the meninges and pericardium 4 months after the administration of a BEAM regimen, achieved a durable (34+ months) complete remission after a second HDCT with cyclophosphamide-TBI. This suggests that TBI may be superior to non-TBI regimens at least in some of these patients.
In conclusion, these results show that HDCT is feasible in patients with MCL or DCL, even those aged above 60 years, and are consistent with recent reports showing that HDCT is a promising treatment option in these patients. Although this is a limited and retrospective series, the overall and progression-free survivals of these patients with DCL or MCL compare favorably with those achieved with any conventional chemotherapy and suggest that HDCT may improve the outcome of these patients. Large multicentric studies comparing HDCT to conventional chemotherapy are required to confirm these results.
